Skip to main content
U.S. flag

An official website of the United States government

Return to Search

340B Drug Pricing Program Requirements

Guidance for covered entities to purchase drugs at the 340B price.

Final

Issued by: Health Resources and Services Administration (HRSA)

Issue Date: December 01, 2020

Program Requirements

Federal Register Notices | Policy Releases | Section 340B of the Public Health Service Act | Program Updates | 340B Program Regulations

To purchase drugs at the 340B price, covered entities must meet the following ongoing requirements: 

  • Keep 340B OPAIS information accurate and up to date. Register new outpatient facilities and contract pharmacies as they are added.
  • Recertify eligibility every year.
  • Prevent diversion to ineligible patients (PDF). Covered entities must not resell or otherwise transfer 340B drugs to ineligible patients.
  • Duplicate Discount Prohibition Manufacturers are prohibited from providing a discounted 340B price and a Medicaid drug rebate for the same drug. Covered entities must accurately report how they bill Medicaid fee-for-service drugs on the Medicaid Exclusion File, as mandated by 42 USC 256b(a)(5)(A)(i).
  • Prepare for program audits. Maintain auditable records documenting compliance with 340B Program requirements. Covered entities are subject to audit by manufacturers or the federal government. Any covered entity that fails to comply with 340B Program requirements may be liable to manufacturers for refunds of the discounts obtained.

Disproportionate Share Hospitals, freestanding cancer hospitals, and children's hospitals must also refrain from participating in a group purchasing organization for covered outpatient drugs. 

It is the covered entity's responsibility to notify drug manufacturers and wholesalers that it will now purchase outpatient drugs at 340B prices. The wholesalers and manufacturers verify the covered entity’s enrollment on the 340B database and must sell its drugs at or below the maximum price determined under the 340B statute.

Date Last Reviewed:  March 2020


HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.